Genmab — April 2016
-
Jeg ved ikke om det har været oppe i debatten, men Castor er jo Late breaking abstract og er med i en plenary session der beskrives sådan her: Plenary Press Briefing – Sunday, June 5, 8:00-9:00 am (CDT)
ASCO’s Plenary Session features studies deemed to have the highest scientific merit and greatest potential impact on patient care. The embargo for studies to be presented in this press briefing will lift at 6:30 am (CDT):
-
-
Tak Mads.
-
God morgen.

-
Tak. Heldigvis har alle andre markeder åbent i dag.

-
Data er netop ikke kendte endnu. Det eneste kendte er hvad der stod i børsmeddelelsen, og der er meget mere. Og alverdens øjne er rettet mod ASCO. Vigtigt er også at Castor kom med efter deadline og at ASCO udnævner studiet to have the highest scientific merit and greatest potential impact on patient care.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind